Myriad Genetics (NASDAQ:MYGN) Issues FY 2024 Earnings Guidance

Myriad Genetics (NASDAQ:MYGN) updated its FY 2024 earnings guidance on Sunday. The company provided EPS guidance of 0.140-0.150 for the period, compared to the consensus EPS estimate of 0.130. The company issued revenue guidance of $836.0 million-$838.0 million, compared to the consensus revenue estimate of $840.2 million.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. UBS Group started coverage on shares of Myriad Genetics in a research report on Tuesday, December 10th. They issued a “neutral” rating and a $18.00 price target on the stock. Stephens reiterated an “equal weight” rating and set a $20.00 target price on shares of Myriad Genetics in a research report on Thursday, January 16th. Morgan Stanley reduced their target price on shares of Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Monday, November 18th. Leerink Partnrs downgraded shares of Myriad Genetics from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 9th. Finally, Leerink Partners downgraded shares of Myriad Genetics from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $30.00 to $21.00 in a research note on Monday, December 9th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Myriad Genetics currently has a consensus rating of “Hold” and a consensus target price of $23.92.

Myriad Genetics Trading Down 1.0 %

Shares of MYGN stock opened at $12.39 on Tuesday. The firm has a fifty day moving average of $14.59 and a 200-day moving average of $21.76. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.90 and a quick ratio of 1.73. Myriad Genetics has a 12-month low of $12.17 and a 12-month high of $29.30.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.